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ABSTRACT 
Somatic cell nuclear transfer and generation of induced pluripotent stem cells 
provide potential routes towards generation of patient specific embryonic stem 
(ES) cells. These procedures require induction of Oct4 gene expression, high 
telomerase activity and specific cell proliferation, characteristics shared with 
cancer stem cells. The aim of this thesis is to gain further understanding of the 
molecular mechanisms that control these events.  
In an attempt to identify factors involved in transcriptional regulation of the 
Oct4, the binding of SAF-A with the Oct4 proximal promoter region in a LIF 
signalling dependent manner was established and subsequently demonstrated to 
be of functional importance for Oct4 transcription. Further investigations 
revealed SAF-A in complex with proven affecters of Oct4 transcription, Oct4 
itself and Sox2, as well as with RNA polymerase II indicating that SAF-A could 
serve to bring together factors required for Oct4 transcription and load them on 
the promoter. Moreover, SAF-A was found in a complex with the SWI/SNF-
Brg1 chromatin remodelling protein in ES and differentiation induced cells. 
Functional assays revealed that dual depletion of SAF-A and Brg1 abolishes 
global transcription by RNA polymerase II indicating a fundamental role for the 
complex in RNA polymerase II mediated transcription. 
The Oct4 expression, as well as its transcriptional regulation were 
investigated in the biopsy samples from ovarian cancer patients. This 
investigation revealed reactivation of the Oct4 expression independently of 
epigenetic regulation in biopsy samples from ovarian cancer patients. Further, 
these patients survived no more than 3.5 years from the diagnosis suggesting 
that Oct4 could be used as a prognostic factor of ovarian cancer mortality.  
Telomere extension by telomerase is mediated by the shelterin complexes. 
The identification and biochemical characterization of the telomere shelterin 
complexes in Xenopus revealed conservation of their main functions in relation 
to human orthologs. Moreover, the temporal regulation of shelterin composition 
and subcomplex appearance was demonstrated during Xenopus embryonic 
development.  
In screening for Tpt1 interacting factors in ES cells, Npm1 was found. The 
interaction occurred in a cell cycle dependent manner and subsequent functional 
assays proved its involvement in cell proliferation.  
In conclusion, new insights regarding Oct4 transcriptional regulation, 
telomere maintenance and ES cell proliferation are presented in this thesis. 
 
Key words: embryonic stem cells, Oct4, SAF-A, Brg1, Tpt1, Npm1, 
transcriptional regulation, cell proliferation, shelterin 
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ABBREVIATIONS 
Brg1  Brahma related gene 1 
BrdU  5-bromo-2-deoxyuridine 
BMP4   bone morphogenetic protein 4 
Cdk  cyclin dependent kinases 
ChIP  chromatin immunoprecipitation 
CTD  C-terminal domain 
DE  distal enhancer 
DNase I  deoxyribonuclease I 
DNMT  DNA methyltransferase 
EdU  5'-ethynyl-2'deoxyuridine 
ES cells  embryonic stem cells 
EU  5-ethynyl uridine 
GCNF  germ cell nuclear factor 
ICM  inner cell mass 
Id  inhibitor of differentiation 
IP  immunoprecipitation 
iPS cells  induced pluripotent stem cells  
JAK  Janus-associated tyrosine kinases 
LIF   leukaemia inhibitory factor 
MEF  mouse embryonic fibroblast 
Ncl  nucleolin 
Oct4  octamer binding transcription factor 4 
PE  proximal enhancer 
POT1  protection of the telomeres 1 
PP  proximal promoter 
RAP1  repressor activator protein 
RARE  retinoic acid response element 
RNA pol II  RNA polymerase II 
SAF-A  scaffold attachment factor A 
SCNT  somatic cell nuclear transfer 
SF1  steroidogenic factor 
STAT  signal transducer and activator of transcription 
TERT  telomerase reverse transcriptase 
TIN2  TRF1 interacting protein 
TPP1  TIN2 and POT1 interacting protein 
Tpt1  translationally controlled tumor protein 
TRF  telomeric repeat-binding factor 
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INTRODUCTION 
For the last three decades investigation of embryonic stem (ES) cells has 
resulted in better understanding of the molecular mechanisms involved in the 
differentiation process of ES cells to somatic cells. Under specific in vitro 
culture conditions, ES cells can proliferate indefinitely and are able to 
differentiate into almost all tissue specific cell lineages, if the appropriate 
extrinsic and intrinsic stimuli are provided. These properties make ES cells an 
attractive source for cell replacement therapy in the treatment of 
neurodegenerative diseases, blood disorders and diabetes. Prior to clinical 
significance, some problems still need to be overcome, like tumour formation 
and immunological rejection of the transplanted cells. To avoid the latter 
problem, the cloning of "sheep Dolly" in 1997 [1], more than 40 years after the 
first frogs were cloned [2], and recent generation of induced pluripotent stem 
(iPS) cells [3-6] have exposed the possibility to create patient specific ES-like 
cells whose differentiated progeny could be used in an autologous manner. 
During these reprogramming processes of somatic cells a unique transcriptional 
hierarchy and epigenetic state, high telomerase activity as well as a specific cell 
cycle of ES cells are induced. The aim of the current thesis is to gain further 
understanding of the molecular mechanisms that control these important events.  
 
EMBRYONIC STEM CELLS  
The generation of a new organism is initiated at the formation of a zygote by 
fertilization of an egg cell. The zygote undergoes cleavage and develops into a 
morula. The next important event in embryogenesis is characterized by the first 
specialization resulting in a formation of a hollow sphere of cells, termed a 
blastocyst. The outer layer of the blastocyst, the trophoblast, develops into 
extraembryonic tissues while the cells inside the sphere, termed the inner cell 
mass (ICM), are pluripotent, describing their capacity to specialize into all cell 
types and tissues.  
In 1981, two groups demonstrated derivation of murine ES cells [7, 8] from 
the ICM (Figure 1). Almost 20 years later derivation of human ES cells using 
donated in vitro fertilized leftover embryos was reported [9].  
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Figure 1. Derivation and 
developmental potentials of ES cells. 
The two main characteristics of ES cells 
are unlimited self-renewal and pluripotency, 
i.e capacity to differentiate into all cell types 
in the body. In mice, the most stringent test 
for pluripotency is injection of a labelled ES 
cell into a blastocyst resulting in the 
formation of a germ-line chimera [10]. Since 
this practice is not applicable in humans for 
ethical and practical reasons, the pluripotency 
of human as well as murine ES cells can be 
demonstrated either in response to specific 
stimuli in vitro or by teratoma formation 
following injection of ES cells in adult 
immunosuppressed mice [11]. In addition to 
self-renewal and pluripotency, ES cell 
characteristics include high nucleo-
cytoplasmic ratio, prominent nucleoli, 
positive staining for alkaline phosphatase, 
rapid cell proliferation, high telomerase 
activity and expression of specific 
pluripotency markers.  
 
APPLICATIONS OF EMBRYONIC STEM CELLS 
Given the possibility of forming a chimera, the derivation of murine ES cells 
has revolutionized the research of gene functions. Currently, the use of gene 
targeting to assess the gene functions in the living mouse is a routine procedure 
and can be performed with inducible systems allowing manipulation of gene 
expression at specific stages in specific cell populations [12]. In addition to 
developmental biology, ES cells provide a powerful tool in the areas of drug 
discovery and drug development [13] as well as for studying the underlying 
mechanisms of diseases [14, 15]. However, the expanding interest in ES cell 
research is in regard to their therapeutic potential for treatment of 
neurodegenerative diseases, blood disorders and diabetes.  
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REACQUISITION OF PLURIPOTENCY 
An important first step to achieve the goal of ES cell based therapeutic 
approaches is the generation of patient specific ES cells. These autologous cells 
could be, after correction of genetic mutations, differentiated into required cell 
types or tissues and transplanted into the patient. However, specialized somatic 
cells are generally unable to reacquire the ES cell state due to their stable 
activation and repression of gene expression. These dramatic changes can be 
induced experimentally by nuclear reprogramming. Although, there are several 
potential techniques resulting in nuclear reprogramming, the focus here is on 
somatic cell nuclear transfer (SCNT) and induced pluripotent stem (iPS) cell 
generation (Figure 2).  
 
 
Figure 2. Schematic illustration of two possible procedures generating patient specific cells. 
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SOMATIC CELL NUCLEAR TRANSFER (SCNT) 
In 1959, before ES cells were derived or any insights on regulators of 
pluripotency were available, it was successfully demonstrated that pluripotent 
state could be reacquired by somatic cell nuclear transfer (SCNT or cloning) in 
amphibians by John Gurdon [2]. During this procedure, the nucleus from a 
differentiated cell is transplanted into an enucleated egg cell and an embryo 
with identical DNA content to the donor is obtained (Figure 2). However, it 
took almost 40 years until SCNT was successfully used for generation of 
mammals [1]. The birth of the first normally developed mammal, the sheep 
Dolly, in addition to human ES cell generation exposed the possibility of 
therapeutic cloning which might be achieved by derivation of pluripotent cells 
from SCNT embryos, subsequent correction of genetic mutations, in vitro 
differentiation into homogeneous population of functional cells, and use for cell 
therapy (Figure 2). Since the birth of the sheep Dolly, SCNT was successfully 
performed in other species such as cow, mouse, goat, pig, cat, and rabbit [16]. 
Recently, it has also been shown that SCNT can produce human blastocyst 
stage embryos at an efficiency of 23% [17].  
The therapeutic potential [18-20] and the equivalency between ES cells 
derived from natural and SCNT embryos [21, 22] have been demonstrated in 
mouse model. However, the success of SCNT is not complete. The vast 
majority of embryos reconstructed by nuclear transfer in animals either die 
before birth or produce unhealthy offspring. In addition to donor cell cycle stage 
and developmental stage of donor cells, the faulty epigenetic reprogramming 
has been proposed as the major cause of developmental failure and abnormal 
phenotypes in these animals [23]. Another limitation of SCNT is the 
requirement of donor oocytes resulting in ethical concerns. Moreover, human 
ES cells have not been derived by SCNT which is essential for proposed 
therapeutic treatments. Despite these limitations, SCNT is the most efficient 
nuclear reprogramming method to generate blastocyst embryos from which ES 
cells can be established.  
INDUCED PLURIPOTENT STEM CELLS (IPS CELLS) 
In 2006, it was demonstrated that pluripotency can be reacquired in mouse 
fibroblasts by retrovirus-mediated introduction of the four transcription factors 
Oct4, Sox2, Klf4 and c-Myc (Figure 2) [3]. These cells were termed induced 
pluripotent stem (iPS) cells. Subsequently, human iPS cells were successfully 
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generated by using the same set of factors, as used earlier in mouse model, as 
well as other factors [4-6, 24, 25].  
The demonstrated reprogramming without the requirement for oocytes 
represents the major advantage of iPS cell generation in comparison to SCNT. 
In addition, the therapeutic potential of iPS cells in combination with genetic 
repair has already been successfully shown in mouse models of sickle cell 
anemia, Parkinson’s disease, Duchenne muscular dystrophy (DMD) and 
hemophilia A [26-29]. However, there are some limitations regarding 
therapeutic applications of these cells such as use of oncogenes i.e. c-Myc, 
Oct4, Sox2 and Klf4 [30-32] as well as retroviruses in their initial generation. 
Subsequent investigations demonstrated that iPS cells can be generated without 
c-Myc with reduced reprogramming efficiency [5, 25, 33] and apart from Oct4 
all other transcription factors have been successfully replaced by another 
member of the same protein family [34]. New strategies involving non-
integrating vectors [35-39], excisable integrating vectors [40-43] and direct 
delivery of four recombinant reprogramming proteins [44] have successfully 
been employed for generation of transgene-free iPS cells. Other limitations of 
iPS cell generation such as low effectiveness and slow reprogramming process 
are limitations that remain. 
REGULATORS OF PLURIPOTENCY  
For the purpose of developing ES cell based therapeutic approaches as well as 
understanding SCNT and iPS cell generation, the thorough knowledge of 
molecular mechanisms that underlie the pluripotency and self-renewal of ES 
cells is required. Below, some of the present knowledge regarding these 
mechanisms will be discussed. 
EXTRINSIC REGULATORS OF PLURIPOTENCY  
Murine ES cells were established and maintained on a feeder layer of 
mitotically inactivated mouse embryonic fibroblasts (MEFs) [7, 8]. Subsequent 
studies identified leukaemia inhibitory factor (LIF) as a MEF-secreted 
component having major impact on pluripotency maintenance of ES cells [45, 
46]. In the absence of LIF signalling these cells differentiate into primitive 
endoderm and mesoderm [47].  
LIF is a member of IL-6 cytokine family. It binds to its receptor (LIFR) 
which recruits gp130 to form a high affinity heterodimer complex. Formation of 
LIFR-gp130 heterodimers leads to the rapid activation of Janus-associated 
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tyrosine kinases (JAKs) followed by phosphorylation, dimerization and thereby 
activation of signal transducer and activation of transcription (STAT). 
Specifically, the ability of LIF to maintain ES cell state in the presence of serum 
is dependent upon activation of STAT3 [48, 49]. It has also been demonstrated 
that bone morphogenetic protein (BMP4) can replace the requirement for serum 
but not that of LIF in maintaining undifferentiated state of ES cells. BMP4 acts 
by inducing inhibitor of differentiation (Id) pathway to block neural 
differentiation [50]. In conclusion, LIF has a pivotal role in maintaining 
undifferentiated state of murine ES cells independently on culturing conditions.  
The regulation of human ES cell lines differs from that of the mouse (Figure 
3). It has been reported that LIF signalling is not sufficient to maintain self-
renewal [9, 51, 52] while BMP4 induces differentiation of human ES cells to 
trophoblast [53]. The central importance for pluripotency and self-renewal of 
human ES cells is regarded bFGF and activin signalling [54, 55]. Differences in 
characteristic signalling pathways between murine and human ES cells might be 
dedicated to different developmental stages of embryos from which the cells are 
derived.  
 
 
 
 
 
 
INTRINSIC REGULATORS OF PLURIPOTENCY 
Besides these extrinsic factors, there are intrinsic factors, discussed in this 
thesis, that have pivotal role for specifying the undifferentiated state of both 
murine and human ES cells. One of these is a unique transcriptional hierarchy 
characterized partially by transcription factor Oct4 and specific epigenetic 
marks. ES cells also display high levels of telomerase activity and TERT 
expression, both of which are rapidly down-regulated during differentiation [56] 
and are much lower or absent in somatic cells. Further, the cell cycle of ES cells 
is very specific [57]. Therefore, high telomerase activity or the expression of 
Figure 3. Extrinsic regulators of pluripotency in ES cells. 
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TERT and an ES specific cell cycle can be regarded as other markers of 
undifferentiated ES cells (Figure 4). Each of these will be discussed below. 
 
 
 
 
 
TRANSCRIPTIONAL REGULATION 
The completion of the sequencing of the human genome provided a base to a 
new era in biology and medicine. However, the identification of the DNA 
sequence is of restricted importance since the character and developmental stage 
of a cell is defined by its constituent proteins, which are the result of specific 
patterns of gene expression. Thus, each developmental stage is characterized by 
its respective gene expression profile and a knowledge regarding regulation of 
the gene expression in ES cells is of central importance for gaining insight in 
pluripotency maintenance.  
Gene expression is a multistep process involving epigenetic events, 
transcription, RNA processing, RNA export and translation. Epigenetic events 
are involved in modifications of DNA, i.e. DNA methylation, and chromatin 
remodelling which are altered during differentiation of ES cells.  
In the mammalian genome, DNA methylation occurs on the cytosine 
residues in the context of CpG dinucleotides and is generally associated with 
stable transcriptional repression of particular genes. DNA methylation levels 
change during early mouse development. Shortly after fertilization, there is a 
subsequent wave of active paternal DNA demethylation. The maternal genome 
is also demethylated but in a replication dependent manner [58]. The patterns of 
DNA methylation are initially established during the blastocyst stage of 
embryonic development by DNMT3A and DNMT3B [58-60] in a process 
called de novo methylation. These epigenetic marks are reproduced during 
Figure 4. Intrinsic regulators of pluripotency in ES cells. 
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successive rounds of mitosis by DNMT1 [61]. Human ES cells were 
demonstrated to possess a unique DNA methylation pattern in comparison to 
differentiated and cancer cells supporting a concept of DNA methylation 
contributing to the undifferentiated state of ES cells [62-64].  
ES cells are also known to have a greater proportion of their genome as less 
condensed euchromatin with acethylated H3 and H4 histones as well as tri-
methylated histone H3 at lysine which are generally associated with 
transcriptional activity [65, 66]. Further, ES cell chromatin is characterized by 
simultaneous presence of both activating and repressive histone modifications at 
lineage-specific genes suggesting presence of silent but primed state of 
activation [66, 67] which probably promotes ES cell plasticity. During 
differentiation, repressive histone modifications are erased from activated 
lineage-specific promoters whereas activating histone modifications are erased 
from promoters that remain silent. These covalent modifications of histone 
amino termini are affected by the activity of chromatin remodelling enzymes 
such as histone acetyl transferases (HATs), histone deacetylases (HDACs), 
histone methyl transferases (HMT) and histone demethylases.  
The other category of chromatin remodelling enzymes utilizes the hydrolysis 
of ATP to disrupt contacts between histones and DNA resulting in alterations of 
nucleosome conformation, position and higher order chromatin structure [68]. 
This is achieved either by sliding the nucleosomes [69] or by inducing a DNA 
twist in the absence of histone movement [70]. The well characterized family of 
ATP dependent chromatin remodelling complexes is SWItch/Sucrose 
NonFermentable (SWI/SNF). SWI/SNF complexes have been implicated in 
regulation of pluripotency [71, 72] and posses a catalytic subunit that 
preferentially interacts with acetylated histones [73]. In mammals, the SWI/SNF 
complexes consist of approximately 10 subunits and ATPases enzymatic 
activity is achieved by either Brahma (Brm) or Brahma related gene 1 (Brg1). 
Despite the fact that Brm and Brg1share a high degree of amino acid sequence 
identity, only Brg1 has been proven important during early embryonic 
development. Brg1 gene knock-out has been demonstrated lethal at the 
blastocyst stage of development [74] and maternally derived Brg1 has been 
reported required for zygotic genome activation [75].  
These mechanisms represent the final effect in the transcriptional hierarchy 
mediated by binding of sequence specific transcription factors to accessible 
DNA regulatory sequences situated upstream of the transcription initiation sites 
i.e. promoter regions. The activity of transcription factors is regulated by 
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numerous signal transduction pathways and is one of the most important steps 
in the control of pluripotency. Three transcription factors i.e. Oct4, Sox2 and 
Nanog, have been reported central for the transcriptional regulatory hierarchy 
that specifies ES cell identity. Recently, the identification of the common target 
sites of these transcription factors by chromatin immunoprecipitation (ChIP) 
assay in combination with genome-wide localization analysis has suggested the 
existence of a regulatory network that maintains pluripotency [76, 77].  
These experiments together with Oct4’s necessity in iPS cell generation [34] 
highlight it as the most important transcription factor for maintenance and 
reacquisition of pluripotency. Below, some of the properties and present 
knowledge regarding transcriptional regulation of Oct4 gene will be discussed. 
 
OCT4 
Oct4 (also referred to as Oct3, Pou5f1, Oct3/4, Oct-4, NF-A3) is one of the 
most important transcription factors during embryogenesis regulating either 
positively or negatively expression of a broad range of target genes [78]. It is a 
member of POU domain family of octamer binding proteins consisting of POU 
specific (POUs) and POU homeo (POUh) domains which are connected via a 
linker. These domains make specific contact with DNA through a helix-turn-
helix structure and recognize a consensus octamer motif ATGCAAAT [79].  
The Oct4 expression profile follows a strict developmentally regulated 
pattern and is involved in the maintenance of an undifferentiated, pluripotent 
embryonic cell state during the first and second lineage determinations in the 
early mouse embryo [80]. In line with its embryonic expression pattern, Oct4 is 
expressed in ES, embryonic carcinoma (EC) and embryonic germ (EG) cells 
[81, 82].  
Oct4 has proven essential during early mouse development. Mouse embryos 
lacking Oct4 die due to a defective ICM consisting of only trophoectoderm 
[81]. Further, the critical level of Oct4 is required to maintain pluripotency of 
ES cells [83]; a twofold increase in Oct4 expression causes differentiation into 
primitive endoderm and mesoderm lineage also generated upon withdrawal of 
LIF [47], whereas a reduction of Oct4 to less than 50% triggers differentiation 
into trophectoderm correlating with the phenotype of Oct4 deficient embryos 
[81]. Ectopic Oct4 expression has been observed in a variety of tumours such as 
ovarian, prostate and gastric tumours [30, 84-86]. Thus, the failure to maintain 
Oct4 levels within narrow limits can disrupt normal development and contribute 
to tumour development.  
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Oct4 regulation 
The expression of Oct4 is controlled by specific upstream regulatory sequences 
(Figure 5). Oct4 gene expression is driven by a TATA-less minimal promoter 
(proximal promoter) which is located within the first 250 bp of the transcription 
initiation site. In addition to the proximal promoter (PP), two enhancer regions 
are important for expression of the Oct4 gene. The proximal enhancer (PE) is 
required for Oct4 expression in the epiblast, while the distal enhancer (DE) 
region drives expression in the morula, ICM and primordial germ cells [87]. 
Comparison between the upstream sequences of human, bovine and mouse Oct4 
promoters revealed four conserved regions. Within these regions, there is a 
number of important nucleotide sequences where factors involved in gene 
regulation can bind. In the proximal promoter, a putative Sp1/Sp3, 
steroidogenic factor (SF-1), Retinoic Acid Response Element (RARE) and 1A-
like (or CTCF) binding sites have been proposed (Figure 5) [88, 89].  
 
 
 
 
 
 
 
 
 
 
Previous studies have shown that the Sp1/Sp3 [90] transcription factor and 
several members of the nuclear receptor family, including GCNF [91], LRH-1 
[92], SF-1 [93], RAR/RXR and COUP TF I/II [94], may be implicated in Oct4 
expression by binding to its proximal promoter region. Of these, GCNF is the 
best validated because Oct4 expression in GCNF deficient embryos is not 
repressed efficiently in somatic cells indicating that GCNF is the repressor of 
Oct4 [91].  
In addition to DNA-binding transcription factors which regulate expression 
of Oct4 genes, its transcription is also regulated by DNA methylation due to the 
CG-rich promoter region. CpG sites in Oct4 promoter are unmethylated in ES 
cells and become methylated in somatic cells in which Oct4 is not expressed. 
Thus, to reactivate Oct4 properly in cloned embryos, somatic cell nuclei may 
need to undergo extensive demethylation of the Oct4 promoter during nuclear 
Figure 5. Schematic 
illustration of Oct4 gene 
regulatory regions. 
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reprogramming [95]. When somatic nuclei were injected to oocytes from 
Xenopus laevis, Oct4 transcription was reactivated [96, 97]. It was shown that 
oocytes have an activity that can demethylate repressed genes and that this may 
be an essential part of the nuclear reprogramming process [97]. Gadd45a was 
recently identified as participating in the DNA demethylation activity in 
Xenopus laevis, indicating that active demethylation occurs by a DNA repair 
mechanism [98]. 
ChIP assays revealed that histones binding to Oct4 enhancer/promoter region 
are hyperacetylated, but hypomethylated, in ES cells. The primary chromatin 
remodelling determinants
 
on Oct4 and
 
Nanog are acetylation of H3K9 and 
demethylation of dimethylated H3K9 during reprogramming by embryonic 
carcinoma (EC) cell extracts [99]. 
Post-translational modifications, such as sumoylation [100] and 
ubiquitination [101], are also known to modify the activity of Oct4. 
TELOMERE MAINTENANCE 
Telomeres are unique DNA-protein structures constituting the final 5-20 kb
 
of 
all human and 10-80 kb of all mouse
 
chromosomes ending in a 100-200 
nucleotide 3'-single stranded overhangs [102, 103]. Telomeres play an essential 
role in the control of genomic stability by allowing cells to distinguish natural 
chromosome ends from damaged DNA and protecting chromosomes against 
degradation and fusion [104, 105].  
In most human cells, telomeres shorten during successive rounds of mitosis 
due to the incomplete replication of linear DNA molecules and
 
the absence of 
elongating mechanisms [106]. As an exception, cell types that proliferate 
indefinitely including ES [54] and cancer cells maintain their telomeres at a 
constant length.
 
In such cells, the enzyme telomerase adds TTAGGG repeats to 
chromosome ends and thereby maintains the telomere length [107-109]. 
Telomerase is a ribonucleoprotein enzyme that contains two core components, 
telomerase reverse transcriptase (TERT) and telomerase RNA (TR). The RNA 
component serves as an integral template for de novo synthesis of telomeric 
DNA.  
The elongation by telomerase depends on the conformation of the telomeric 
DNA [110, 111]. It has been shown that telomeric overhangs can fold back and 
anneal with the double stranded complementary sequence forming T-loop 
which can facilitate formation of a higher order structure. This process is 
modulated by shelterin complex which is also proposed to regulate telomere 
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protection [112]. Shelterin complex consists of six proteins: TRF1, TRF2, 
TIN2, RAP1, POT1 and TPP1 (Figure 6).  
 
 
 
 
 
TRF1 [113] and TRF2 [114, 115] are homodimeric proteins that bind double-
stranded telomeric DNA via the C-terminal Myb domain [113]. The difference 
between these proteins is demonstrated in their N-terminus; TRF1 has an acidic 
N-terminus while TRF2 has an alkaline N-terminus [115]. TRF1 and TRF2 
regulate formation of the T-loop and thereby indirectly the telomere extension 
by giving telomerase access to the telomeres. However, TRF1 and TRF2 do not 
directly associate with each other, but interact with other components of 
shelterin complex such as TIN2 [116] and RAP1 [117].  
The TRF1 interacting nuclear protein (TIN2) [116, 118] is a linchpin in the 
telomeric complex. The N- terminus of TIN2 binds TRF2 while its C-terminus 
binds TRF1.  
The telomeric single-stranded 3’ overhangs are directly bound by the 
protection of the telomeres 1 (POT1) protein via an oligosaccharide or 
oligonucleotide binding (OB) domain [119, 120]. POT1 interacts indirectly with 
TRF1 and TRF2 via TIN2 and TPP1, and thereby affects synthesis of telomeric 
DNA by telomerase [121-126]. TPP1 (TIN2 and POT1 interacting protein) 
bridges the interaction between POT1 and TIN2. It is also referred as PTOP 
(POT1 and TIN2 organizing protein), PIP1 (POT1 interacting protein) and 
TINT1 (TIN2 interacting protein). TPP1 contains a functional nuclear localising 
signal and localizes to both the cytoplasm and the nucleus, where it binds to 
POT1 and TIN2 and regulates assembly of the shelterin complex [127].  
Figure 6. Schematic of shelterin complex on telomeric DNA. 
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The repressor activator protein 1 (RAP1) contains BRCT, Myb, a coiled-coil 
and RCT domains. The Myb domain has no detectable DNA binding activity. 
The RCT domain is responsible for its association with TRF2 [117].  
In addition to their established roles in cellular aging, stem cell biology and 
cancer [128-130], telomeres have recently been proposed functionally important 
in epigenetic gene regulation and vertebrate embryonic development [131, 132]. 
In animals generated by SCNT, telomere length in somatic cells has been found 
to be comparable with that in age-matched normally fertilized animals 
suggesting that the enucleated oocyte has the ability to reset the telomere length 
of the donor somatic cell by the elongation of telomeres [133-135]. 
CELL CYCLE 
All cells reproduce by duplicating their genetic content and segregating copies 
precisely into two genetically identical daughter cells during a cell cycle. 
However, the cell cycle of differentiated somatic and ES cells differ in 
structural and consequently temporal perspectives. Generally, the cell cycle of 
somatic cells is composed of S phase and M phase which are separated by gap 
phases, G1 and G2, allowing cell cycle progression to be regulated by various 
intracellular and extracellular signals. Unlike to somatic cells, ES cells divide 
very rapidly owing to a truncated G1 phase. Murine and human ES cells transit 
the cell cycle once every 8-12h and 15-30h, respectively [57, 136]. This ES cell 
capacity reflects unusually rapid proliferative rates of the cells that they 
originate from.  
The cell cycle progression is controlled by the control system consisting of 
cyclin-dependent kinases (Cdks) [137] in complex with cyclins. The cyclins 
introduce conformational changes and partial activation of Cdks. Cdk-cyclin 
complexes are required for proper transition from one cell cycle phase to the 
next and therefore have to be activated at precise points of the cell cycle. The 
activation of Cdk-cyclin complexes is controlled at multiple levels, including 
complex assembly, regulation of cyclin levels, post-translational modifications 
of the Cdk subunit, Cdk complex localization and by modulation of Cdk 
inhibitor (CKI) levels. 
In somatic cells, passage from G1 into S phase normally requires Cdk4 and 6 
as well as cyclins D and E. ES cell division is driven by modest Cdk6-cyclin D 
and constitutively high Cdk2-cyclin E and Cdk2-cyclin A levels. The activity of 
only Cdk1-cyclin B is regulated during the cell cycle phases of ES cells [57] 
(Figure 7). Further, in somatic cells there are checkpoints which are missing in 
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the ES cell cycle. These permit an arrest in cell cycle progression if previous 
events have not been completed and should be seen as accessory systems that 
have been added to provide a more sophisticated form of regulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CANCER STEM CELLS 
It has been established that ES and cancer cells share several molecular 
properties including self-renewal and differentiation capacity. Evidence 
demonstrate that many pathways that are generally associated with cancer also 
are implicated in regulation of ES cells. Thus, the concept of cancer stem cells 
have evolved hypothesizing presence of small population of immortalized adult 
stem cells that have been dedifferentiated. These cells have been detected in 
leukaemia, brain tumours, breast cancer and pancreatic cancer [138-143]. The 
concept of the cancer stem cell is further strengthened by previously mentioned 
observation that Oct4 is reactivated in a variety of tumours [84-86].  
Figure 7. Schematics 
representing ES cell specific 
cell cycle control systems.  
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ASPECTS ON METHODOLOGY 
IDENTIFICATION OF PROTEIN BINDING DNA SITES  
EMSA (PAPER IV) 
Electrophoretic mobility shift assay (EMSA) is a method to study the 
interaction of a protein with a DNA sequence. It works on the basis that the 
interaction of an in vitro translated protein (or protein present in the extract) 
with DNA retards the mobility of the DNA by non-denaturing polyacrylamide 
gel electrophoresis (PAGE). The major advantages of EMSA are high 
specificity and simplicity of the procedure.  
In experiments described in paper IV EMSA was employed to characterize 
the binding of in vitro translated shelterin proteins to the telomeric DNA 
sequence.  
 
DNASE I FOOTPRINTING (PAPER I) 
DNase I footprinting technique has been a very useful method in gaining 
information about the location of a protein binding site in the DNA sequence. In 
footprinting experiments the interaction with a protein protects the DNA in the 
binding region from the cleavage of an endonuclease such as deoxyribonuclease 
I (DNase I). When this approach is used in combination with dideoxy 
sequencing analysis, the DNA sequence to which the protein is bound is 
resolved. This method is highly specific and is often used despite being 
technically more difficult than EMSA.  
In experiments described in paper I, we aimed to identify differential 
protection of the non-methylated and methylated Oct4 regulatory region due to 
the differentiation status of cells used for extract preparation.  
IDENTIFICATION OF DNA ASSOCIATED PROTEINS 
DNA AFFINITY CHROMATOGRAPHY (PAPER I) 
DNA affinity chromatography is a technique used for the purification of DNA 
binding proteins. Various supports such as Sepharose, cellulose and silica can 
be used for coupling of non-specific or specific DNA by several coupling 
chemistries.  
In experiments described in paper I, the footprint region was covalently 
coupled to the cyanogen bromide-activated Sepharose®4B with the major 
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advantage of low non-specific protein binding [144]. The DNA associated 
proteins from extracts prepared from ES and differentiation induced cells were 
enriched and by nano-LC-FT-ICR mass spectrometry analysis identified. 
VERIFICATION OF DNA-PROTEIN INTERACTIONS 
CHROMATIN IMMUNOPRECIPITATION (PAPER I) 
The aforementioned techniques provide information about DNA-protein 
binding specificities in vitro. However, it is essential to gain information about 
binding of particular protein to specific gene regulatory regions in the context of 
a cellular system. Chromatin immunoprecipitation (ChIP) is a method that has 
been used in this purpose. The crosslinked protein-DNA complexes are 
sonicated into small fragments and immunoprecipitated. Following 
immunoprecipitation, crosslinking is reversed, proteins are removed and the 
DNA is recovered. The DNA is then screened by PCR to determine if specific 
gene regulatory region was bound by the protein of interest.  
Sequential chromatin immunoprecipitation (Re-ChIP) is used to address 
whether two proteins can simultaneously co-occupy a stretch of DNA in cells. 
The protein–DNA complexes are formaldehyde-crosslinked and subjected to 
two sequential immunoprecipitations with antibodies of different specificity. 
In paper I binding of the identified protein and its simultaneous co-
occupancy with RNA polymerase II to different Oct4 regulatory regions during 
two different conditions, i.e. pluripotency and induced differentiation, were 
investigated. Optimisation of a crosslinking and sonication steps were 
performed. Two control samples were included in each experimental setup; the 
input sample indicating presence and amount of chromatin used in the ChIP 
reaction and no antibody sample indicating the amount of background signal. 
The quantification of immunoprecipitated DNA by ChIP and Re-ChIP was 
performed by Real-Time and conventional PCR, respectively.  
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DETECTION OF CDNA AND PROTEIN LEVELS 
QUANTITATIVE REVERSE TRANSCRIPTASE PCR (PAPER I, II, IV, V) 
Reverse transcriptase polymerase chain reaction (RT-PCR) is used in paper I, II, 
IV and V to amplify, detect and quantitatively determine specific RNA-
transcripts by reverse transcription of RNA to cDNA and subsequent Real-Time 
PCR using SYBR Green dye.  
In described experiments two step RT-PCR and standard curve methods 
were used to estimate mRNA levels.  
 
IMMUNOBLOTTING (PAPER I, II, III, V) 
Immunoblotting, also known as Western blot, is a commonly used technique 
that allows detection of the presence, relative amount and molecular weight of a 
specific antigen separated by the size on SDS polyacrylamide gel followed by 
transfer to a synthetic membrane and subsequent detection by the antigen 
specific antibody. Optimisation of a transfer and blocking efficiency as well as 
antibody concentration are important for obtaining high quality 
immunoblotting. 
 
IMMUNOFLUORESCENCE (PAPER I, II, III, V) 
Immunofluorescence is commonly used antibody-based method to detect 
presence and localization of a specific antigen in cells. One of the main 
difficulties with immunofluorescence is overcoming non-specific background 
fluorescence. Optimisation of fixation times, pre-treatment with blocking 
agents, concentration of both primary and secondary antibodies are important 
for obtaining high quality immunostaining.  
In experiments described in paper I, II, III and V immunofluorescence was 
followed by confocal microscopy, an important tool to visualize presence and 
localization of the specific antigen in the cell. In comparison to conventional 
wide-field optical microscopy it offers several advantages including the ability 
to choose focal plane, to eliminate or reduce out-of-focus background 
fluorescence as well as to collect serial sections from thick samples. In addition, 
in our experiments we sequentially scanned various fluorophores to reduce 
possible crossover and bleed-through which can be a significant problem with 
simultaneous multiple-wavelength excitations. 
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IDENTIFICATION OF PROTEIN-PROTEIN INTERACTIONS 
IN VITRO BINDING PROTEIN ASSAY (PAPER V) 
In vitro binding protein assay is used to identify protein-protein interactions. It 
is based on coupling of an in vitro translated protein to the support and 
purification of its interacting partners by incubation with protein extract.  
In paper V in vitro translated protein of interest was coupled to the cyanogen 
bromide-activated Sepharose®4B and its interacting partners were purified 
from extracts prepared from ES cells. Nano-LC-FT-ICR mass spectrometry 
analysis was used to identify the purified proteins. 
 
CO-IMMUNOPRECIPITATION (PAPER I, II, V) 
Co-immunoprecipitation (Co-IP) involves immunoprecipitation of intact 
protein-protein complexes by an antibody that targets a known protein that is 
believed to be a member of a larger protein complex. Generally co-IP is 
followed by immunoblotting to detect the proteins in the complex. The 
approach is usually used for epitope-tagged proteins. However, in papers I, II 
and V endogenous complexes between proteins are detected. Each experimental 
setup contained a IgG control for comparison.  
 
IN SITU PROXIMITY LIGATION ASSAY (PAPER I, II, V) 
In situ proximity ligation (in situ PLA) assay is a method to investigate protein-
protein complexes and to visualize their spatial and temporal changes occurring 
naturally or as a cause of different cellular treatments [145]. The in situ PLA is 
based on recognition of proteins by pairs of antibodies raised in different 
species. A specie specific secondary antibodies with attached DNA strands 
participate in ligation, replication and sequence visualizing reactions. The major 
advantages of this method are the ability to visualize and simultaneously 
quantitatively determine spatial and temporal localization of the endogenous 
protein complexes within the cells and to detect even few protein-protein 
complexes. However, the specificity and sensitivity of the method is dependent 
on the accuracy of the primary antibodies.  
In papers I and II the in situ PLA was employed to investigate differentiation 
mediated changes in protein complexes. In these experiments ES cells were 
induced to differentiate by either withdrawal of LIF or addition of retinoic acid 
from/to culturing media. To analyze the involvement of different kinases on 
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investigated protein-protein complexes in paper V, ES cells were treated with 
two different Plk1 inhibitors (BI2536 or wortmannin) and one Cdk-cyclin 
inhibitor (purvalanol A) prior to in situ PLA analysis. Control samples such as 
an internal control for individual comparison, i.e. one treated and one non-
treated sample, as well as technical and biological controls were included in 
each experimental setup to eliminate experimental variances from different 
experiments.  
PROTEIN FUNCTION 
TRANSFECTION (PAPER I, II, V) 
To study the effect of knock-down or over-expression of specific gene 
genetically modified cells have to be generated. The generally used method to 
introduce exogenous gene material into cells, such as siRNA, shRNA or 
transgene vectors, is transfection which is not effective in ES cells.  
In papers I, II and V we accessed high efficiency in delivering siRNA, 
SureSilencing™ shRNA and pEPI-eGFP-vector into ES cells by liposome-
based transfection with HiPerfect and Lipofectamine LTX (Invitrogen) four 
hours post seeding [146], respectively. Twenty four hours post transfection, 
selection for shRNA transfected cells was started by adding optimized 
concentration of puromycin. The effect of gene knock-down was detected by 
either Real-Time RT-PCR, immunoblotting or immunofluorescence. In over-
expression experiments the autonomously replicating pEPI-eGFP vector was 
used. The effect of gene over-expression was detected by immunofluorescence. 
 
CELL PROLIFERATION (PAPER V) 
Cell proliferation assay was used in paper V to examine the number of cells still 
being able to synthesize new DNA following RNA interference. This was 
examined using a novel alternative to BrdU, a thymidine analog 5'-ethynyl-
2'deoxyuridine (EdU, Click-iT
TM 
EdU Imaging Kit, Invitrogen) that is 
incorporated efficiently into DNA for measuring DNA synthesis [147]. In 
comparison to BrdU, the advantage of EdU is that it does not require DNA 
denaturation since it uses small molecules for detection and consequently not 
affect the additional antibody staining.  
 
 
   Dzeneta Vizlin Hodzic 
27 
 
GLOBAL TRANSCRIPTION (PAPER I, II) 
Global transcription assay was used in paper I and II to examine the number of 
cells still being able to transcribe following RNA interference. This was 
examined using a novel alternative to both radioactive nucleoside labelling and 
BrU, an uridine analog 5-ethynyl uridine (EU, Click-iT®RNA Imaging Kit, 
Invitrogen) that incorporates efficiently into nascent RNA [148]. In comparison 
to radioactive nucleoside labelling and BrU incorporation, EU allows spatial 
determination of transcripts in high-resolution and faster whole-mount staining 
of large organs and tissue fragments. 
DETECTION OF DNA METHYLATION  
BISULFITE SEQUENCING (PAPER III) 
Bisulfite sequencing involves the treatment of genomic DNA with sodium 
bisulfite which deaminates unmethylated cytosines converting them into 
uraciles. Methylated cytosines are not changed. The sodium bisulfite treatment 
is followed by PCR and sequencing. By comparison of the sequences from 
sodium bisulfite untreated and treated DNA, the unmethylated and methylated 
sites are revealed.  
The advantage of this method is that it obtains single base-pair resolution for 
specific regions. However, it is dependent on highly efficient bisulfite 
conversion.  
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AIMS 
Methodologies to reprogram somatic cells into patient specific pluripotent cells, 
which could potentially be used in drug discovery and cell replacement 
therapies, are currently advancing. Previous studies have revealed a unique 
transcriptional hierarchy and epigenetic state, high telomerase activity as well as 
specific cell cycle to be of pivotal importance for the pluripotency of ES cells 
and the success of reprogramming. The overall aim of this thesis has been to 
gain further understanding of the molecular mechanisms that control these 
important events in ES cells.  
 
More specifically, the aims of the included papers were: 
 
 To gain further understanding regarding the transcriptional activation of 
pluripotency marker Oct4 in ES cells (Paper I) 
 
 To find novel interacting partners to identified Oct4 regulator (Paper II) 
 
 To investigate the oncogenic properties of Oct4 in patients suffering 
from ovarian cancer (Paper III) 
 
 To identify and characterize the telomere shelterin complexes in 
Xenopus laevis and tropicalis, two commonly used model organisms for 
developmental biology studies (Paper IV) 
  
 To gain further understanding regarding Tpt1 which is suggested 
important for the effectiveness of SCNT (Paper V) 
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RESULTS AND DISCUSSION 
PAPER I - SAF-A HAS A ROLE IN TRANSCRIPTIONAL 
REGULATION OF OCT4 IN ES CELLS 
 
Oct4 expression has been proven essential for the formation of the ICM from 
which ES cells originate [81] and for successful iPS cell creation [34]. 
However, molecular details regarding Oct4 transcriptional activation in ES cells 
are not completely understood.  
 
ENDOGENOUS SAF-A BINDS OCT4 PROXIMAL PROMOTER  
In an attempt to identify factor/factors involved in transcriptional regulation of 
Oct4, we first screened for sequence specific binding differences at the 
evolutionary conserved Oct4 proximal promoter region using in vitro DNase I 
footprinting. Protein extracts prepared from ES and by LIF withdrawal 
differentiation induced cells were used. The most prominent difference in 
protection, based on differentiation mediated by LIF withdrawal, was observed 
in the 1A-like region which has been shown important for active demethylation 
of the Oct4 proximal promoter and reactivation of the Oct4 gene during SCNT 
in Xenopus oocytes [97]. By using DNA affinity chromatography followed by 
SDS-PAGE, DNA binding of a 120 kDa factor from exclusively ES cell extract 
was revealed. Since these findings were in accordance with our in vitro DNase I 
footprinting results, the 120 kDa band was excised from the gel and identified 
by nano-LC-FT-ICR mass spectrometry analysis to be SAF-A, also referred to 
as hnRNP U. SAF-A is an abundant nuclear protein which contains an 
arginine/glycine-rich region (RGG box) located in the C-terminus and SAP 
motif in the N-termimus responsible for its binding to RNA and single/double 
stranded DNA, respectively [149, 150]. We found it a good candidate due to its 
proposed involvement in gene specific transcriptional regulation of 
apolipoprotein D, Bmal1 and developmentally regulated Shh and Klf2 genes 
[151-154]. Moreover, no viable SAF-A knock-out mice have been reported, 
however hypomorphic mutations in the noncoding region of SAF-A resulted in 
post-implantation lethality at E6.5 [155], suggesting its vital importance during 
early development and contribution to a variety of essential biological 
functions. 
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Since the assays employed, i.e. DNase I footprinting and DNA affinity 
chromatography, gave information regarding in vitro binding of proteins to 
regulatory region, we sought to investigate proposed presence of SAF-A at the 
Oct4 promoter in ES cells. ChIP followed by Real-Time PCR was performed 
and demonstrated preferential presence of SAF-A at the Oct4 proximal 
promoter in ES cells while induction of differentiation by LIF withdrawal 
resulted in a decline of SAF-A binding. The similar pattern of SAF-A binding 
was revealed also at the Nanog promoter. These results strengthen the notion of 
SAF-A's presence at the Oct4 proximal promoter in ES cells and are in 
accordance with aforementioned reports suggesting association of SAF-A with 
elements in the promoter region of developmentally regulated Shh and Klf2 
genes [152, 153].  
 
FUNCTIONAL IMPORTANCE OF SAF-A 
The next issue addressed regarded the function of SAF-A in ES cells. To 
explore SAF-A’s role on global transcription, RNA interference mediated 
decreases of SAF-A in combination with incorporation of EU and 
immunofluorescence were used. SAF-A depletion had temporal impact on 
global transcription. SAF-A depletion for 48 hours had no effect on the 
proportion of transcriptionally active ES cells while prolonged depletion for a 
total of 72 hours decreased the number of transcriptionally active cells by 57% 
in comparison to the control.  
These results in addition to recent reports that SAF-A might interact with the 
CTD of RNA polymerase II (RNA pol II) [156, 157] intrigued us to examine a 
possible interaction between SAF-A and RNA pol II in ES cells. In situ PLA 
and co-immunoprecipitation experiments revealed that endogenous SAF-A 
could be found in complex with endogenous RNA pol II independently of CTD 
phosphorylation, mRNA and induced differentiation. These results suggest two 
distinct but not mutually exclusive roles for SAF-A: the complex between SAF-
A and pCTD-RNA pol II reflects transcriptional elongation events and the 
complex between SAF-A and npCTD-RNA pol II reflects transcriptional 
initiation events.  
Next, we investigated the simultaneous binding of SAF-A and RNA pol II at 
two specific Oct4 regions, one corresponding to transcriptional initiation and 
the other to transcriptional elongation. Sequential ChIP revealed presence of 
SAF-A:RNA pol II complex at the Oct4 proximal promoter but not at the Oct4 
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intron region during pluripotent conditions. These results suggest that SAF-A is 
involved specifically in the transcriptional initiation of Oct4 gene.  
Further, the specific effect of SAF-A on Oct4 transcription was measured by 
Real-Time RT-PCR as well as immunofluorescence in control and SAF-A 
depleted ES cells. SAF-A depletion for 48 hours was accompanied with 
decreased Oct4 mRNA and protein levels. At this time point SAF-A depletion 
did not affect global transcription and therefore the effect on Oct4 expression 
can be considered specific. To strengthen the impact of our findings, rescue 
experiments were performed demonstrating that the ectopic expression of 
human SAF-A could rescue the SAF-A knock-down phenotype. 
SAF-A depletion for 96 hours resulted in decreased mRNA levels of 
housekeeping genes correlating with results from the global transcription assay. 
Although decreased global transcription at this time point was observed, 
Brachyury was up-regulated suggesting a loss of pluripotency and directed 
differentiation along the mesodermal pathway. In accordance, the 
morphological changes of ES cells were observed in SAF-A depleted cells. The 
observed differentiation along the mesodermal pathway is not in accordance 
with previous reports indicating correlation of Oct4 down-regulation with 
differentiation of ES cells into trophectoderm [83]. Notably, the absence of LIF 
signalling induces differentiation of murine ES cells into the mesodermal 
pathway [47] which we observe when SAF-A is depleted in presence of LIF 
signalling. Thus, our RNA interference experiments suggest connection 
between LIF signalling and SAF-A's role in transcriptional regulation of Oct4 
which is in accordance with our initial experiments. 
 
SAF-A IS IN COMPLEX WITH OCT4 AND SOX2  
Given that RNA pol II association factor, Paf1, affects Oct4 expression by the 
interaction with Oct4 protein itself [158, 159] we explored if SAF-A also exists 
in close proximity to endogenous Oct4. In situ PLA revealed endogenous SAF-
A:Oct4 complexes in ES cells. These results are in accordance with report 
suggesting SAF-A in complex with Brn-4, which belongs to the same protein 
family as Oct4 [160].  
Since Oct4 and Sox2 have been previously reported to interact with the Oct4 
enhancer region and thereby regulate Oct4 expression [161, 162], we 
investigated whether SAF-A can also be found in complex with Sox2. In situ 
PLA revealed endogenous SAF-A:Sox2 complexes in ES cells. These findings 
Molecular Mechanisms of Pluripotency 
 
32 
 
might suggest that SAF-A serves to bring together factors required for Oct4 
expression in ES cells and load them on the promoter together with RNA pol II. 
The suggestion is strengthened by the fact that the number of SAF-A:Oct4 
complexes decreased approximately by 70 % upon induction of differentiation 
by LIF withdrawal for two days, although Oct4 levels were not significantly 
reduced during this time period. The number of SAF-A:Sox2 complexes 
decreased to the same extent as well, suggesting that any of these lost 
interactions could be considered as a candidate for controlling SAF-A 
dissociation from the Oct4 proximal promoter.  
The next question addressed the dissociation of SAF-A from the Oct4 
proximal promoter as well as the dissociation of SAF-A:Oct4 and SAF-A:Sox2 
complexes observed upon early differentiation mediated by LIF withdrawal. 
Given that Oct4 protein levels were not significantly affected at this stage of 
differentiation, we reasoned that the observed dissociations could be explained 
by a decrease in SAF-A protein levels. In contrary to our expectations, induced 
differentiation did not decrease either SAF-A mRNA or protein levels. Thus, 
dissociation of SAF-A from the Oct4 proximal promoter as well as dissociation 
of SAF-A:Oct4 and SAF-A:Sox2 complexes and consequently Oct4 down-
regulation cannot be ascribed simply to a decrease in SAF-A levels.  
 
SAF-A IS IN COMPLEX WITH STAT3 
Given that pluripotency of ES cells is dependent on LIF signalling which results 
in STAT3 activation [48] and that SAF-A is not quantitatively affected by 
differentiation induced by LIF withdrawal, we next explored the possible 
interaction between SAF-A and STAT3 in ES cells. In situ PLA revealed 
presence of endogenous SAF-A:STAT3 complexes. Further, the quantity of 
complexes decreased by differentiation induced by LIF withdrawal. These 
observations might provide a link in a chain of interactions ranging from 
extrinsic stimuli by LIF to an intrinsic response which possibly results in Oct4 
transcriptional initiation. However, these observations do not explain either 
dissociation of SAF-A from the Oct4 proximal promoter or dissociation of 
SAF-A:Oct4 and SAF-A:Sox2 complexes mediated by LIF withdrawal since we 
and others [163] have not detected STAT3 associated with the Oct4 promoter.  
Our discoveries allow us to propose a model for Oct4 transcriptional 
initiation. This explains how signalling by extrinsic LIF proceeds via STAT3, 
which translocates into the nucleus [48, 49] and could interact with SAF-A. 
SAF-A binds the Oct4 promoter through to some unknown factors. The 
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transcription factors Oct4 and Sox2 associate with SAF-A. Since Oct4 and Sox2 
have been found to interact preferentially with the enhancer region of the Oct4 
promoter [161, 162] it is likely that the complex with SAF-A, Oct4 and Sox2 
links enhancer with the proximal promoter region. SAF-A next recruits npCTD-
RNA pol II to the transcription start site to initiate Oct4 transcription. Upon 
early differentiation mediated by LIF withdrawal for two days, SAF-A 
association with the Oct4 promoter is reduced followed by blocked 
transcriptional initiation of Oct4.  
 
FUTURE INVESTIGATION 
The remaining question addresses the molecular event responsible for SAF-A 
dissociation. The finding that SAF-A levels do not decrease after LIF 
withdrawal but rather increase suggests that the promoter release is not 
controlled directly by the level of SAF-A. It is possible that in the ES cells a 
modification of SAF-A rather than its mere presence/absence, may be a critical 
parameter for the dissociation of SAF-A from the Oct4 promoter. The approach 
that could be used to reveal this important issue is immunoprecipitation of 
endogenous SAF-A from ES and differentiation induced cells followed by 
nano-LC-FT-ICR mass spectrometry analysis, respectively. However, one must 
consider protein digestion by other enzymes than trypsin since SAF-A digestion 
by trypsin generates either very short or long peptides which are not optimal for 
successful nano-LC-FT-ICR mass spectrometry analysis.  
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PAPER II - SAF-A TOGETHER WITH BRG1 IS REQUIRED FOR 
RNA POLYMERASE II MEDIATED TRANSCRIPTION 
 
In addition to the gene specific regulation by SAF-A, it has also been 
demonstrated to interact with affecters of epigenetic marks, histone acetyl 
transferases [164, 165] to relax chromatin structure. These findings indicate that 
SAF-A participates in various aspects of transcriptional regulation by 
interacting with a wide range of nucleic acids and proteins.  
Given the complexity of the transcriptional regulation by SAF-A, we 
hypothesized that other epigenetic modifiers of nucleosomal structure can be 
found in complex with SAF-A. Therefore we addressed whether SAF-A could 
be detected in association with Brg1, a catalytic subunit of SWI/SNF ATP 
dependent chromatin remodelling complexes, which is reported to preferentially 
interact with acetylated histones [73].  
 
SAF-A IS ASSOCIATED WITH BRG1 IN GENERAL MANNER 
The spatial distribution of endogenous SAF-A and Brg1 was analysed first. We 
found SAF-A and Brg1 localized to the nucleus of ES cells and co-localization 
could be observed by using ImageJ software. Next, co-immunoprecipitation was 
performed demonstrating endogenous Brg1 in the complex with endogenous 
SAF-A. Consistent with co-localization and co-immunoprecipitation 
experiments, the in situ PLA visualized SAF-A:Brg1 complexes in the nucleus 
of ES cells. These findings indicate that endogenous SAF-A and Brg1 are a part 
of the same complex in ES cells. When ES cell differentiation was induced, by 
either LIF withdrawal or addition of retinoic acid, the endogenous SAF-A:Brg1 
complexes remained intact indicating general nature of the complex.  
 
SAF-A:BRG1 COMPLEXES ARE INVOLVED IN RNA POLYMERASE II 
MEDIATED TRANSCRIPTION  
To investigate function of SAF-A:Brg1 complex in ES cells RNA interference 
experiments were performed. The effect of decreased SAF-A and Brg1 protein 
levels on each other's transcription was first assayed. Depletion of one of the 
proteins for 48 hours did not have any effect on expression of the other. 
However, prolonged depletion to a total of 96 hours resulted in decreased levels 
of total mRNA as well as mRNA levels of housekeeping genes.  
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These findings prompted us to investigate the involvement of SAF-A and 
Brg1 alone and as a complex on global transcription in ES cells. The effect of 
decreased protein levels on global transcription was detected by EU 
incorporation followed by immunofluorescence. SAF-A depletion for 48 hours 
had no significant effect on the proportion of transcriptionally active ES cells 
while prolonged depletion for a total of 72 hours decreased it by 57% in 
comparison to the control. The depletion of Brg1 affected global transcription 
also in a temporal manner. Brg1 depletion for 48 hours decreased the proportion 
of transcriptionally active ES cells by 26% while prolonged depletion for a total 
of 72 hours decreased it by 54% in comparison to the shRNA control. 
Interestingly, the dual depletion of SAF-A and Brg1 for 48 and 72 hours 
decreased the proportion of transcriptionally active ES cells by 42% and 92% in 
comparison to the control, respectively. During indicated time period 
incorporation of EU in nucleoli could be observed indicating that RNA pol I 
transcription machinery remained unaffected. Thus, prolonged silencing of the 
proteins to a total of 72 h highlights the pivotal role of the observed complex in 
RNA pol II mediated transcription.  
 
SAF-A:BRG1 COMPLEX IS PARTIALLY ASSOCIATED WITH RNA 
Both SWI/SNF complexes and SAF-A have been proposed to be involved in 
RNA processing [166-168]. To determine whether the association of SAF-A 
with Brg1 is mediated by RNA, the total extracts prepared from ES cells were 
treated with RNase A followed by co-immunoprecipitation. The association of 
SAF-A with Brg1 was decreased by the RNase A treatment although a part of 
the association was resistant to the treatment. These results suggest that there 
are two types of SAF-A:Brg1 association; one independent and the other 
dependent on the presence of RNA.  
Given that both SAF-A and Brg1 have been involved in modification of 
chromatin structure [68, 164, 165], are reported to interact with RNA pol II 
[156, 157, 169] and remain all along the transcribing gene as a component of 
growing RNP particles [168], the observed SAF-A:Brg1 complex could be 
required for many intermediate steps of transcription or link these together.  
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FUTURE INVESTIGATION 
Given that observed SAF-A:Brg1 complex is of fundamental role for RNA pol 
II mediated transcription, it would be very interesting to investigate whether the 
SAF-A:Brg1 association is direct and which protein domains are responsible for 
possible direct association. In this regard, SAF-A and Brg1 constructs should be 
made, proteins expressed and tested for direct association. However, it should 
be mentioned that SAF-A is a very unstable protein and cannot be expressed in 
bacteria.  
Another interesting issue that has not been addressed is whether the 
phenotype observed by the depletion of one of the proteins can be rescued by 
simultaneous over-expressing of the other protein.  
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PAPER III - OCT4 AS A PROGNOSTIC BIOMARKER OF 
OVARIAN CANCER 
 
Ovarian cancer is the most lethal gynaecologic cancer. Current ovarian cancer 
treatments are inefficient at targeting the cells that sustain tumour growth. 
Therefore it is very important to understand the molecular origins of the ovarian 
cancer. It has been suggested that tumors arise from cancer stem cells with 
capacity for self-renewal and differentiation, two characteristics shared with ES 
cells. Given that ectopic Oct4 activation has been suggested as a candidate 
biomarker for cancer stem cells [30, 84, 170], we explored possible reactivation 
of Oct4 gene in patients suffering from ovarian cancer. 
 
OCT4 IS REACTIVATED IN PATIENTS SUFFERING FROM OVARIAN 
CANCER 
To investigate if Oct4 was reactivated in ovarian cancer, Oct4 protein levels in 
the biopsy samples from 20 ovarian cancer patients were analyzed. Western blot 
revealed detectable levels of Oct4 protein in biopsy samples from eight patients 
which is in agreement with recent report demonstrating the presence of Oct4 in 
biopsy samples from ovarian cancer patients [86]. Notably, we found that 
patients with Oct4 expressed survived no more than 3.5 years from the 
diagnosis suggesting that Oct4 could be used as a prognostic factor of mortality 
in women with ovarian cancer.  
 
OCT4 PROMOTER IS NOT DEMETHYLATED IN OVARIAN CANCER TISSUE 
DNA demethylation has previously been reported to be a prerequisite for the 
reactivation of Oct4 [97]. Therefore, two regions of the Oct4 promoter, i.e. PP 
and DE, were analysed with respect to CpG methylation. These analyses 
revealed that ovarian cancer tissue is a very heterogeneous cell population in 
respect to DNA methylation. In contrary to our expectations, the degree of Oct4 
promoter methylation was significantly higher in deceased ovarian cancer 
patients (80.4%) than in those that had been successfully treated (66.9%). 
Similar observation has been reported for promoter region of the catalytic 
subunit of telomerase (TERT) which is reactivated in cancer cell lines [171]. 
Alternatively, our data may indicate that Oct4 is reactivated through a promoter 
switch, which permits Oct4 expression irrespective of methylation status.  
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In summary, our investigation now implicates reactivation of the stem cell 
marker Oct4 in ovarian cancer, and thus indirectly adds support to the concept 
of ovarian cancer stem cells.  
 
FUTURE INVESTIGATION 
It should be marked that method used, i.e. bisulfite sequencing, gives insight of 
DNA methylation at the allele resolution in a single cell. Given that ovarian 
cancer tissue is a very heterogeneous cell population and that the great part of 
the cells probably do not express Oct4, additional methods should be used prior 
bisulfite sequencing to gain more information about correlation of Oct4 
reactivation and Oct4 promoter DNA methylation. One possibility is to employ 
laser based microdissection (LSM) for isolation of Oct4 positive cells from 
ovarian cancer tissue followed by bisulfite sequencing.  
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PAPER IV - DEVELOPMENTAL STUDIES OF XENOPUS 
SHELTERIN COMPLEXES 
 
The recent discovery proposing the importance of telomeres in epigenetic gene 
regulation and vertebrate embryonic development calls for the establishment of 
model organisms to study shelterin and telomere function under normal 
developmental conditions. Therefore, the aim of this project was to identify and 
characterize the telomere shelterin complexes in Xenopus laevis and tropicalis 
which are commonly used model organisms for developmental biology studies.  
 
IDENTIFIED XENOPUS LAEVIS AND TROPICALIS SHELTERIN PROTEINS 
INTERACT WITH TELOMERIC DNA 
Possible orthologs of human shelterin components were identified from 
Xenopus laevis and Xenopus tropicalis cDNA libraries. A clustalW alignment 
of amino acid sequences showed high homology (50-90% and 51-88%; Table1) 
between human (h)/ Xenopus laevis (Xl) and human (h)/ Xenopus tropicalis 
(Xt) ortologs, respectively. The identity was shown to be between 19-50% and 
25-50% (Table1), respectively.  
 
 
 
 
 
 
 
 
 
 
 
The sequence analysis revealed that Xt, as reported Xl, TRF1 contain conserved 
C-terminal MYB/homeodomain and N-terminal domains which are required for 
interaction with telomeric DNA and formation of homodimers, respectively. 
These results are in accordance with EMSA demonstrating that Xenopus TRF1, 
just like hTRF1, binds double stranded telomeric DNA with high affinity and 
specificity in vitro and simultaneously forms a complex with TIN2. The acidic 
N-terminus is missing in XtTRF1 as it previously has been reported for XlTRF1 
Human Xenopus laevis Xenopus tropicalis 
shelterin protein Homology(%) Identity(%) Homology(%) Identity(%) 
hTRF1 85 34 81 32 
hTRF2 90 36 88 36 
hPOT1 67 50 67 50 
hTIN2 66 26 65 25 
hRAP1 77 32 79 33 
hTPP1 50 19 51 20 
hPINX1 78.4 48.5 79 50.3 
Table 1. Homology and identity between human and Xenopus laevis/ tropicalis orthologs. 
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[172]. This domain has been demonstrated to be responsible for interactions 
with the shelterin accessory factor Tankyrase in humans [173]. Because 
Tankyrase regulates binding of TRF1 to the telomeric DNA in humans, the 
missing acidic N-terminus in Xenopus TRF1 likely has implications for TRF1 
regulation by Tankyrase.  
The sequence analysis revealed that XtTRF2, like previously identified 
XlTRF2 [174], shares several features of hTRF2. The C-terminal 
MYB/homeodomain is conserved. The hTRF1 and hTRF2 
MYB/homeodomains have similar affinities for telomeric DNA [175]. The 
hTRF2 is reported to form a highly specific complex with telomeric DNA when 
in complex with RAP1 [112, 117]. The region of hTRF2 that is responsible for 
interactions with RAP1 is conserved in Xenopus as demonstrated by sequence 
analysis. In addition, Xenopus RAP1 contains a putative MYB domain and C-
terminal TRF2 interacting domain. EMSAs reveals that Xenopus RAP1-TRF2 
complex has significantly higher specificity for double stranded telomeric DNA 
than TRF2 on its own. Moreover, the sequence analysis revealed that Xenopus 
TRF2 lacks the basic N-terminus. The functional significance of this domain 
has not been elucidated.  
Further, the sequence analysis revealed that the only detected difference 
between the human and Xenopus POT1 orthologs is that the central linker 
peptide, which connects the two N-terminal DNA-binding OB folds to the C-
terminal protein-interacting OB-fold, is slightly longer in hPOT1. This peptide 
linker is believed to allow the DNA binding module of POT1 to move relative 
to its protein-interacting module, so that shelterin can modulate the structure 
and accessibility of the single-stranded telomeric G-overhang. The binding 
properties, i.e. high affinity and specificity, of Xenopus POT1 to single stranded 
telomeric DNA [121] were confirmed in vitro by EMSA. 
The identified Xenopus TIN2 lacks conserved domains, just like hTIN2 
ortholog. However, the hTIN2 binding domains of hTRF1 (aa 256–276) [118] 
and hTRF2 (aa 1–220) [176, 177] correspond to the highly conserved regions in 
Xenopus orthologs.  
The sequence analysis of TPP1 revealed that fixed secondary structure as 
well as regions responsible for interactions with POT1 are highly conserved 
between human and Xenopus TPP1.  
These studies suggest that identified Xenopus shelterin proteins have 
conserved main domains and functions of their human orthologs.  
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XENOPUS SHELTERIN GENES ARE TEMPORALY REGULATED DURING 
DEVELOPMENT  
The shelterin gene mRNA levels during Xenopus embryogenesis were 
quantified for developmental stages between blastula and gastrula. The 
expression of all shelterin components, as well as the shelterin accessory factor 
PINX1 and telomerase, were changed during embryogenesis. The expression of 
all shelterin genes decreased, but there was no apparent overall covariance 
between their expression profiles. The expression profile of telomerase was 
different from the expression profiles of the shelterin genes. However, 
subgroups of shelterin genes exhibited covariance. The POT1, TPP1 and TIN2 
genes formed a shelterin subgroup whose expression profiles were very similar. 
The expression profile of TRF1 was very similar to that of PINX1, whereas the 
TRF2 and RAP1 genes formed the third shelterin subgroup. These results 
indicate that the composition of shelterin and the formation of its subcomplexes 
appear to be temporally regulated during Xenopus embryonic development.  
 
FUTURE INVESTIGATION 
Our results demonstration high telomerase and shelterin gene expression during 
early embryogenesis may reflect a telomere length-resetting mechanism 
reported for iPS cells [178] and for animals cloned through SCNT [133-135]. 
Since Xenopus shelterin proteins are now identified and SCNT in Xenopus is 
relatively effective, this important issue should be explored by quantitative 
determination of shelterin gene mRNA levels during SCNT in Xenopus.  
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PAPER V - TPT1:NPM1 COMPLEX IS INVOLVED IN CELL 
PROLIFERATION OF ES CELLS 
 
Given that Tpt1, also referred as TCTP, HRF, Fortilin or P23, has been proven 
important for embryonic development [179] and found to affect Oct4 expression 
in Xenopus SCNT [180] as well as the outcome of SCNT in bovine [181], we 
addressed functional importance of this protein in ES cells.  
 
TPT1 SUBCELLULAR LOCALIZATION CHANGES DURING 
DIFFERENTIATION 
Tpt1 is highly conserved and abundant eukaryotic protein. Conflicting results 
have been reported regarding the cellular localization of Tpt1 [182, 183]. Using 
western blot and immunofluorescence analysis, we detected Tpt1 localized to 
both cytoplasm and nucleus in ES cells. When differentiation was induced, by 
either LIF withdrawal or addition of RA, preferential cytoplasmic localization 
and decreased protein levels of Tpt1 were detected. These data are in agreement 
with the previous reports suggesting high Tpt1 levels in ES cells [184-186] 
which are decreasing during neuronal lineage commitment [187].  
 
TPT1 INTERACTS WITH NPM1 IN A CELL CYCLE DEPENDENT MANNER 
To explore the function of Tpt1 in ES cells, we first screened for novel Tpt1 
interaction partners using recombinant Tpt1 protein covalently linked to 
cyanogen bromide activated sepharose beads. The beads were incubated with 
ES cell extract. Potential Tpt1 binding factors were eluted with increasing ionic 
strength and fractionated by SDS-PAGE. Bands of interest were excised from 
the gel and by nano-LC-FT-IRC mass spectrometry analysis identified. The 
band corresponding to 38 kDa in the 0.7 M NaCl elute was identified to be 
Npm1, also referred as B23, NO38 or numatrin, which has been reported 
expressed in high levels in both murine and human ES cells [184, 185].  
Immunofluorescence analysis in combination with BioPix iQ 2.0 software 
revealed the significantly higher co-localization of Tpt1 and Npm1 in mitotic in 
comparison to interphase ES cells. These results were confirmed by in situ PLA. 
Additionally, Npm1 was co-immunoprecipitated using anti-Tpt1, further 
strengthening the observed results that endogenous Tpt1 and Npm1 interact in 
ES cells.  
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TPT1 AND NPM1 INTERACT INDEPENDENTLY OF PLK1 
PHOSPHORYLATION 
Both Tpt1 and Npm1 have previously been demonstrated to be phosphorylated 
by Plk1 during mitosis [188, 189]. To investigate whether the Tpt1:Npm1 
interaction is regulated by Plk1 phosphorylation, ES cells were treated with two 
different Plk1 inhibitors, wortmannin [190] and BI2536 [191], which arrest cell 
cycle progression at metaphase and prophase, respectively. While wortmannin 
treatment resulted in weaker intensity and decreased quantity of PLA signals, 
the BI2536 treatment did not affect either quantity or intensity of PLA signals. 
These contradictory results could have several possible explanations. BI2536 is 
a specific Plk1 inhibitor, while wortmannin also inhibits several other kinases. 
The observation that BI2536 have no effect on Tpt1:Npm1 interaction might 
therefore indicate that other kinases than Plk1 regulate Tpt1:Npm1 interaction. 
The alternative explanation might be that Plk1 indeed is involved in regulation 
but that it occurs in later stages of mitosis. Overall, these results reveal that the 
Tpt1: Npm1 interaction is not dependent on Plk1 mediated phosphorylation, at 
least not during the early stages of mitosis.  
 
TPT1:NPM1 COMPLEXES ARE INVOLVED IN ES CELL PROLIFERATION 
To investigate the impact of Tpt1 and Npm1 alone or as a complex on cell 
proliferation, ES cells were manipulated by either over-expression or depletion 
of indicated proteins followed by EdU proliferation assay and confocal 
microscopy.  
Npm1 over-expression resulted in increased proliferation in ES cells 
(14.7%). In contrary, increased levels of Tpt1 had decreasing effect on ES cell 
proliferation (15.9%). This is in accordance with earlier studies in other cellular 
systems reporting slow growing cells as a result of Tpt1 over-expression [192]. 
Interestingly, dual over-expression of Tpt1 and Npm1 stabilized proliferation to 
normal ES cell rate.  
Depletion of Tpt1 and Npm1 alone for 48 and 72 hours resulted in 
significant decrease in cell proliferation. Moreover, ES cells depleted for both 
Tpt1 and Npm1 exhibited yet larger reduction in proliferation in comparison to 
cells depleted for Tpt1 and Npm1 alone.  
Our discoveries propose a role for the Tpt1:Npm1 complex in ES cell 
proliferation and are in accordance with previous reports suggesting the role of 
Tpt1 and Npm1 in cell proliferation in different cellular systems [188, 192-196]. 
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The over-expression experiments indicate that Tpt1 and Npm1 do not have 
redundant roles and therefore both proteins are of great importance in regulating 
ES cell proliferation. The observation that over-expression as well as depletion 
of Tpt1 decreases ES cell proliferation indicates that there is a critical level of 
the protein that is pivotal for this event to occur which is also a possible 
explanation regarding its importance for cloning.  
 
FUTURE INVESTIGATION 
Given that observed Tpt1:Npm1 interaction is important for proper ES cell 
proliferation and probably is conserved in cancer cells, it is very important to 
identify protein domains and subsequently investigate the mechanisms 
responsible for the observed interaction.  
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CONCLUDING REMARKS 
 SAF-A was found to bind preferentially to the Oct4 proximal promoter in 
ES cells. Functional assays revealed that depletion of SAF-A affects Oct4 
mRNA and protein levels. Further, SAF-A was found in the complex with 
a previously proven affecters of Oct4 expression, Oct4 and Sox2, in a LIF 
signalling dependent manner as well as with RNA pol II suggesting that 
SAF-A serves to bring together factors required for Oct4 expression and 
load them on the promoter together with RNA pol II in ES cells.  
 
 SAF-A was found in complex with the SWI/SNF-Brg1 chromatin 
remodelling protein in ES and differentiation induced cells. Functional 
assays revealed that dual depletion of SAF-A and Brg1 in ES cells 
abolishes global transcription by RNA polymerase II indicating a 
fundamental role for the SAF-A/Brg1 complex in RNA polymerase II 
mediated transcription.  
 
 Ectopic Oct4 expression was found in the biopsy samples from ovarian 
cancer patients who survived for no more than 3.5 years from the diagnosis 
suggesting that Oct4 could be used as a prognostic factor of mortality in 
women with ovarian cancer. Further, observed Oct4 reactivation was not 
dependent on DNA demethylation of the investigated Oct4 regulatory 
regions. 
 
 Xenopus shelterin proteins as well as the shelterin accessory factor were 
identified and the conservation of main functions in relation to their human 
orthologs was demonstrated by in vitro expression and biochemical 
characterization. Moreover, the temporal regulation of shelterin 
composition and subcomplex appearance was demonstrated during 
Xenopus embryonic development.  
 
 Tpt1 was found to interact with Npm1 in a cell cycle dependent manner, 
with a significant peak during mitosis. Functional assays revealed that dual 
depletion of Tpt1 and Npm1 results in larger decrease in cell proliferation 
than their combined individual decreases.  
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